Boston Scientific's stent data flawed

Boston Scientific's new heart stent, awaiting approval for U.S. sales, is backed by flawed research despite the company's claims of success in a clinical trial, according to a Wall Street Journal review of the data. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.